Affordable Health Care for Every American
Peter strongly believes that every American has a right to affordable health care. He is fighting to cut the skyrocketing cost of prescription drugs and advance cost-effective telemedicine technology.
- Pass Medicare for All
- Allow the importation of safe prescription drugs from Canada
- Cut the cost of prescription drugs for seniors by using Medicare’s purchasing power to demand a better deal from drug companies
- Remove barriers to the development of low cost generic drugs
- Block any attempt to overturn Roe v. Wade and repeal the Hyde Amendment
- Fully fund Planned Parenthood and Title X family planning services
- Provide significant resources to communities on the front lines of opioid epidemic
- Increase funding for NIH disease and drug research
More on Affordable Health Care for Every American
WASHINGTON – This evening, by a vote of 234-183, the House of Representatives approved a multi-pronged health care package (H.R. 987) that will lower prescription drug prices and increase access to health care coverage through the Affordable Care Act (ACA).
The final bill includes five provisions written or co-sponsored by Rep. Peter Welch (D-Vt.). Video of Welch speaking on the bill can be found HERE.
WASHINGTON – Representative Peter Welch (D-Vt.) joined a bipartisan group of House and Senate members yesterday in introducing legislation to stop brand name drug company abuse of the drug approval process in order to block or slow more affordable generic drugs from coming to market.
The Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act would curb the common brand company practice of filing sham “citizen petitions” during the drug approval process that masquerade as public comments.
RUTLAND, Vt. – At a press conference this afternoon at Rutland Pharmacy, Rep. Peter Welch (D-Vt.) unveiled two bills that will protect Vermont’s local independent pharmacies that are at risk due to anti-competitive practices by middlemen in the prescription drug market. There are 41 independent pharmacies in Vermont employing 381 full time employees.
WASHINGTON, D.C. – Late yesterday, the House passed legislation introduced by Rep. Peter Welch (D-Vt.) that closes a loophole in the Medicaid program benefitting drug companies. The loophole allows the companies to minimize drug discounts they are required to provide to state and federal Medicaid programs.
BURLINGTON – At a press conference today at Community Health Centers of Burlington, Rep.
WASHINGTON—Rep. Peter Welch (D-Vt.) and Rep. David McKinley (R-W.Va.) today introduced the Fair Access for Safe and Timely (FAST) Generics Act. The legislation would thwart manipulation of the Food and Drug Administration’s (FDA) drug safety regulations in order to block the production of generic alternatives to brand name medicines. This would increase consumer access to generic drugs, boost market competition, and ultimately save consumers money. The FAST Generics Act is cosponsored by Rep. David Cicilline (D-R.I.).
WASHINGTON — Members of Congress from both parties served notice on pharmaceutical companies on Tuesday that the days of unchecked drug-price increases were over and that they would be held politically accountable for exorbitant prices.
The new reality became apparent at simultaneous but separate hearings of House and Senate committees where lawmakers said that the relentless increases were unsustainable and unacceptable.
WASHINGTON, D.C. – Reps. Peter Welch (D-Vt.) and Morgan Griffith (R-Va.) today reintroduced the Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. The legislation would ensure that community pharmacists receive reimbursement at the rate posted at the time prescriptions are filled by prohibiting Medicare Part D plan sponsors and pharmacy benefit managers (PBMs) from retroactively reducing payments on accurate reimbursement claims submitted by pharmacies.
WASHINGTON - Rep. Peter Welch (D-Vt.) has been reappointed to the House Committee on Oversight and Reform. The committee has broad jurisdiction over executive branch programs and activities. Welch has served on the committee since he was first elected to Congress in 2006.
WASHINGTON – Reps. Peter Welch (D-Vt.) and Francis Rooney (R-Fla.) sent a letter late Friday to federal regulators demanding scrutiny of the impact on consumers of the pending merger of two pharmaceutical giants, Celgene and Bristol-Myers Squibb.